Call(WhatsApp Us)
+8615360806100Email Us
cherry@laeyo.comSee the factory by live video walkthrough
Book an on-site factory visit in GuangzhouConsumer use panels are where most Middle East skincare launches are won or lost — not in the lab. A formula that performs in a 20-person panel in Shanghai or New Jersey can fail…
Consumer use panels are where most Middle East skincare launches are won or lost — not in the lab. A formula that performs in a 20-person panel in Shanghai or New Jersey can fail a 60-person panel in Riyadh or Dubai for reasons that have nothing to do with the formula: the tone distribution was wrong, the panel was recruited in the wrong season, the questionnaire was translated rather than validated, or the panel was run during Ramadan and nobody recorded fasting status as a variable. This guide is written for brand owners and sourcing managers who need to specify a panel that will survive scrutiny — by a retailer, a distributor, a regulator, or a customer reading the claim on the pack. It covers quota design, objective skin tone measurement, screening instruments, Arabic questionnaire validation, seasonal and calendar effects, and the exact documents to request from your manufacturer before you pay a deposit. Informational only, not legal or regulatory advice.
Most briefs arrive at the factory as “we need a 4-week consumer use test, n=50.” That is not a specification — it is a budget line. Before a panel partner is briefed, the claim architecture has to be fixed, because the claim determines the quota, the instrument, the duration, and the season.
Write the claim first, then work backwards to the panel. If the brief cannot state the claim in one sentence, the panel is not ready to be recruited.
The single most common defect in Middle East panels is a tone distribution borrowed from a global template. In GCC markets, tan and brown tones are the majority, not the subgroup. Quotas should reflect both the market population and the claim’s risk profile — a “no white cast” sunscreen claim needs the darker bands deliberately over-sampled, not proportionally represented.
| Panel segment | Typical quota | Screening method | Why it changes the result |
|---|---|---|---|
| Light–intermediate tone | 20–30% | Chromameter ITA° 28–55 | Residue and cast are least visible here; over-weighting this band hides defects |
| Tan tone | 30–40% | Chromameter ITA° 10–28 | Largest real-world group in most GCC markets; often under-recruited |
| Brown–dark tone | 20–30% | ITA° <10 plus melanin index | Ashiness, grey cast, and post-inflammatory risk only appear in this band |
| Oily / combination skin | 40–60% | Sebumeter plus self-report | Drives pilling, greasiness, and texture complaints under heat and humidity |
| Dry skin | 20–30% | Corneometer and TEWL at baseline | Where stinging, tightness, and richness complaints concentrate |
| Self-perceived sensitive | 20–30% (subset n≥30) | Sensitive Scale-10 plus lactic acid sting test | Needed for tolerability claims; self-declaration alone is too broad |
| Occlusive coverage users | 30–50% where relevant | Screening question on hijab/abaya coverage hours | Covered skin changes TEWL, sweat, friction, and fragrance irritation risk |
Add a hard rule to the protocol: no single tone band may fall below n=15 if the claim mentions tone, radiance, or residue. Below that threshold, subgroup results are anecdotal and should not appear on pack.
Fitzpatrick typing describes UV response and photoaging risk. It is not a colour scale, and it is operator-dependent: two technicians will type the same volunteer differently. For recruitment, use an instrumental measure and predefine the bands in the protocol.
Ask for the raw baseline measurements, not just the summary table. If the panel partner cannot supply per-subject ITA° values, you cannot verify the quota was met.
Self-declared sensitive skin is a poor enrolment criterion on its own. Self-perception is influenced by climate, cleansing habits, and prior product experiences, and prevalence varies widely across populations. Use a two-step screen:
Whichever instruments you choose, freeze them in the protocol. Switching instruments mid-study invalidates the dataset, and switching between sites is worse.
An Arabic questionnaire that was machine-translated from English will produce data you cannot defend. Requirements to specify:
Middle East panels run in conditions that global protocols rarely account for, and the effects are large enough to flip a result.
Recruitment quality is a procurement variable, not an operational detail. Specify these controls in the contract:
Send this list as a written request before the study is quoted. Each item should have a named owner and a measurable acceptance criterion.
The compression lever in a panel study is not the number of subjects — it is the number of sequential approvals. Run translation, recruitment, and regulatory review in parallel wherever the protocol allows.
| Phase | Duration | Buyer action | Manufacturer / partner action | Evidence output |
|---|---|---|---|---|
| Claim and protocol lock | 1–2 weeks | Approve final claim list and quota table | Draft protocol and analysis plan | Signed protocol v1.0 |
| Questionnaire validation | 2–3 weeks | Review translated items | Forward–back translation, cognitive debriefing | Translation log and debrief report |
| Recruitment and screening | 2–4 weeks | Confirm quotas and venue | Recruit, ID-verify, instrument baseline | Baseline dataset and quota reconciliation |
| Use period | 2–8 weeks | Monitor interim complaint reports | Run visits, diaries, dermatological assessment | Visit records and adverse event log |
| Analysis and reporting | 2–4 weeks | Approve claim wording against results | Statistical analysis, final report, raw data handover | Final report, raw dataset, substantiation file |
| Regulatory review | 1–3 weeks (parallel) | Submit to local consultant | Supply documentation on request | Written claim opinion |
Fastest safe path: compress recruitment by using an existing verified panel database, and run regulatory review in parallel from week one. Do not compress the use period, the washout, or the questionnaire debriefing. Standard path: add two weeks to recruitment for hard-to-fill tone bands and one extra week for site-specific seasonal scheduling.
| Symptom | Root cause | Prevention | What to request from the factory |
|---|---|---|---|
| Tone-evenness claim collapses at review | Panel under-recruited dark tones; n per band too small | Fixed quota table with a minimum per band | Per-subject ITA° and melanin index at baseline |
| High satisfaction score, low repurchase intent in market | Acquiescence bias and interviewer-administered scales | Reverse-scored items, self-administered digital capture | Full item-level response file, not summary percentages |
| Sunscreen performs in test, complaints about greasiness in market | Panel run in cool season or air-conditioned venue only | Season-matched testing with site temperature and humidity logged | Visit-level environmental log and usage diary |
| Irritation complaints among covered-skin users | Occlusion and friction not represented in the panel | Quota for occlusive coverage hours; record coverage in diary | Coverage-hours screening field and dermatological assessment sheets |
| Study timeline slips by three weeks | Recruitment started during Ramadan or Eid travel window | Calendar review before recruitment opens | Recruitment schedule with calendar assumptions stated |
| Report cannot be used for registration | Missing calibration records, consent forms, or analysis plan | Document checklist signed off before first visit | Calibration certificates, consent templates, signed analysis plan |
| Claim wording rejected locally | Panel data validated a claim the market does not permit | Regulatory review of claim list before protocol lock | Written local regulatory opinion referenced to each claim |
| Package and product interaction surfaces late | Panel used bulk-filled jars, not the production pack | Test the commercial pack, including pump and closure | Packaging compatibility report and in-use pack photographs |
As a working baseline: 30–50 subjects for a perception study on a single segment, 60–100 where a percentage claim will appear on pack, and at least 15 per tone band for any subgroup result you intend to publish. Comparative claims and tolerability claims need a statistician-defined sample size, not a rule of thumb.
Only if the protocol documents site as a variable. Skin tone distribution, humidity, water hardness, and cleansing habits differ between coastal and inland sites and between markets. A pooled report without a site breakdown will not survive a distributor’s technical review.
A questionnaire supports perception claims. Instrumental data supports efficacy claims. If your pack says “clinically proven,” “visibly reduces,” or names a percentage change, you need instrumental endpoints with calibration records and a predefined analysis plan.
Fasting changes hydration, sleep, and cleansing frequency, and Eid travel affects attendance. The defensible approach is either to schedule outside the period or to record fasting status at every visit and treat it as a covariate in the analysis. Undocumented scheduling is the failure mode.
Missing calibration records and missing per-subject baseline data. Both are cheap to produce at the time and impossible to reconstruct afterwards, and both are the first things a regulatory reviewer or a retailer’s technical team will ask for.
Ready to scope a panel that matches your claim, market, and launch date? Share your target markets, SKU list and formats, positioning, packaging direction, and timeline — and we will come back with a protocol outline, quota table, and evidence checklist rather than a generic quotation. Request a Quote.